Related Experiment Video
Updated: May 22, 2026
07:18
A Behavioral Test Battery for the Repeated Assessment of Motor Skills, Mood, and Cognition in Mice
Published on: March 2, 2019
Dementia and behavioral neurology: recent advances
Basar Bilgic1, Hasmet A Hanagasi, Murat Emre
1Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Capa, 34093, Istanbul, Turkey. bbilgic@istanbul.edu.tr
Journal of Neurology
|April 25, 2012
Summary
This review summarizes recent advancements in dementia and behavioral neurology research. Key findings from the Journal of Neurology
Area of Science:
- Neurology
- Behavioral Neurology
- Dementia Research
Background:
- The Journal of Neurology is a leading publication in neurological sciences.
- Dementia and behavioral neurology represent critical areas of ongoing medical research.
- Understanding recent progress is vital for clinical practice and future research directions.
Purpose of the Study:
- To provide a comprehensive summary of research progress in dementia and behavioral neurology.
- To highlight key studies published in the Journal of Neurology over the past year.
- To offer insights into the current state of the field.
Main Methods:
- Systematic review of articles published in the Journal of Neurology.
- Focus on research within the domains of dementia and behavioral neurology.
- Analysis of findings reported in the past year's publications.
Main Results:
- Summarized key advancements in understanding dementia subtypes.
- Highlighted new insights into behavioral changes associated with neurological disorders.
- Identified emerging trends in diagnostic and therapeutic research.
Conclusions:
- The past year has seen significant progress in dementia and behavioral neurology.
- Continued research in these areas is crucial for improving patient outcomes.
- The Journal of Neurology remains a key source for cutting-edge research in the field.
Related Concept Videos
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...